# A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

> **NCT03561701** · PHASE3 · COMPLETED · sponsor: **Mycovia Pharmaceuticals Inc.** · enrollment: 425 (actual)

## Conditions studied

- Recurrent Vulvovaginal Candidiasis

## Interventions

- **DRUG:** Oteseconazole (VT-1161)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03561701
- **Lead sponsor:** Mycovia Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2020-10-13
- **Final completion:** 2021-08-03
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03561701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03561701, "A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03561701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*